Latest News
-
Monday - June 21, 2021
Not intended for U.S. and UK Media
Bayer submits regulatory applications for oncology treatment combination of copanlisib and rituximab in the U.S. and EU
In the US, Bayer has filed for relapsed indolent B-cell non-Hodgkin’s lymphoma (B-iNHL) / In the EU, Bayer has filed for relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted / Filings based on results from Phase III trial CHRONOS-3 showing a significant improvement in the primary endpoint of progression-free survival for the combination of copanlisib and rituximab in patients with relapsed iNHL » more
-
Tuesday - June 8, 2021
Bayer to advance two first-of-its-kind cell and gene therapies for Parkinson’s disease
Parkinson’s disease is most common neurodegenerative movement disorder / It impacts more than 10 million people worldwide/ No function-restoring therapy is currently available / Bayer is pursuing a two-pronged approach to deliver transformative therapies with one cell and one gene therapy candidate in clinical trials » more
-
Thursday - June 3, 2021
Not intended for U.S. and UK Media
Bayer acquires Noria and PSMA Therapeutics to expand portfolio in prostate cancer
Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer » more
-
Wednesday - June 2, 2021
Researchers with unique ideas on helping farmers protect their crops selected as Bayer 2021 Grants4Ag awardees
24 scientists will receive both financial and scientific support for their crop science research proposal / Successful projects have the potential to become future collaborations with Bayer / Researchers selected from more than 600 proposals representing 39 countries » more
-
Thursday - May 27, 2021
Leaps by Bayer leads USD 90 Million Series B financing in digital health company Ada Health
Ada Health combines medical knowledge with powerful AI to revolutionize possibilities for personal health for patients globally / Investment to support advancement of Ada’s symptom assessment and care navigation platform » more
-
Thursday - May 27, 2021
Conference Call for investors and media
Address by Werner Baumann
Chairman of the Board of Management » more
-
Thursday - May 27, 2021
Bayer announces five-point plan to effectively address potential future Roundup™ claims » more
-
Wednesday - May 26, 2021
Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine
Collaboration combines BlueRock’s leading induced pluripotent stem cell (iPSC) platform technology and genome biology expertise with Senti Bio’s proprietary gene circuit technology platform, including Smart Sensors and Regulator Dials » more
-
Tuesday - May 25, 2021
AskBio Announces IND for LION-101, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), Cleared to Proceed by U.S. FDA
LGMD2I/R9 is a Rare Form of Muscular Dystrophy with No Approved Therapies / First-in-Human Phase 1/2 Clinical Study Expected to Begin Dosing in 1H 2022 » more
-
Tuesday - May 25, 2021
Not intended for U.S. and UK Media
Precision oncology treatment Larotrectinib submitted for marketing authorization in China » more
-
Friday - May 21, 2021
Not intended for U.S. and UK Media
Positive CHMP opinion for Bayer’s new symptomatic chronic heart failure treatment vericiguat
Vericiguat is being considered for adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring intravenous therapy / Vericiguat was studied in a population with a high risk of cardiovascular death or heart failure hospitalization / European Commission decision is expected in the coming months » more
-
Wednesday - May 19, 2021
Not intended for U.S. and UK Media - ASCO Annual Meeting 2021:
Long-term data on Vitrakvi™ (larotrectinib) confirm sustained clinical benefit of greater than four years in patients with TRK fusion cancer regardless of tumor type and age
Larotrectinib achieved 75% (95% CI 68-81) overall response rate (ORR) and median duration of response (DoR) of 49.3 months (95% CI 27.3-not estimable [NE]) in expanded integrated dataset of 206 evaluable adults and children with TRK fusion cancer, which occurs when an NTRK gene fuses with another unrelated gene, across 21 different tumor types and regardless of age (range: 0.1-84 years) with longer follow-up at a median follow-up of 22.3 months / In tumor-specific analyses, larotrectinib demonstrated rapid and durable responses, and long disease control, among patients with lung and primary central nervous system (CNS) TRK fusion cancers / Intra-patient comparison showed majority of TRK fusion cancer patients experienced a meaningful clinical benefit with larotrectinib compared to their prior line of therapy / Majority of adverse events (AEs) were Grade 1 or 2 and no new safety signals were identified » more
-
Wednesday - May 19, 2021
Bayer launches additional commercial varieties with intermediate resistance to Tomato Brown Rugose Fruit Virus (ToBRFV) and announces new tomato varieties with high resistance in pipeline
Varieties will allow growers to protect their yield without leaf and fruit symptoms / Combinations of resistance in Bayer’s pre-commercial pipeline could protect against ToBRFV even under high pressure conditions » more
-
Tuesday - May 18, 2021
Bayer announces new commercial leaders for Crop Science Division to accelerate growth and drive business transformation » more
-
Monday - May 17, 2021
BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases » more
-
Monday - May 17, 2021
Not intended for U.S. and UK Media - Late-Breaking Data from exploratory analysis of Phase III FIDELIO-DKD study presented at the American College of Cardiology’s (ACC) 70th Annual Scientific Session (ACC.21)
Finerenone has potential to reduce the risk of new onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes
A prespecified exploratory analysis of the FIDELIO-DKD study demonstrates that finerenone may significantly reduce the risk of new onset atrial fibrillation or flutter (AFF) in patients with CKD and T2D versus placebo when added to standard of care / This analysis also concluded that finerenone reduced the risk of kidney or cardiovascular events with no significant difference in the effect of finerenone between patients with and without history of AFF at baseline / Based on the comprehensive finerenone clinical trial program, finerenone is the first investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist to demonstrate cardiovascular and renal benefits in patients with chronic kidney disease and type 2 diabetes / Results from the exploratory analysis were simultaneously published in the Journal of the American College of Cardiology » more
-
Monday - May 17, 2021
Not intended for U.S. and UK Media
Large real-world study shows benefit of rivaroxaban in patients with nonvalvular atrial fibrillation with type 2 diabetes
Real-world data contribute to findings from pivotal clinical trial / Data show that rivaroxaban was associated with reduced serious complications and death in patients with nonvalvular atrial fibrillation (NVAF) and comorbid type 2 diabetes (T2D) compared to warfarin / The findings come from the large study RIVA-DM which evaluated the effectiveness and safety of rivaroxaban versus warfarin in patients with NVAF and T2D, focusing on endpoints including the risk of vascular death, bleeding-related hospitalization, and stroke as well as kidney and limb related complications » more
-
Monday - May 17, 2021
Bayer brings “Feeding a Hungry Planet” into focus by inviting young leaders around the globe to apply for the 5th biennial Youth Ag Summit
100 chosen delegates will be invited to a virtual global forum on November 16-17 / Bayer will collaborate with the United Nation’s Sustainable Development Solutions Network (SDSN) and Babele on a 10-week Youth Ag Summit (YAS) University following the forum with online mentoring from industry leaders and YAS alumni Applications close June 30, 2021 » more
-
Wednesday - May 12, 2021
First quarter of 2021:
Bayer: successful start to 2021
Good operational performance – sales and earnings negatively impacted by currency of 938 million euros and 337 million euros / Group sales up by 2.8 percent (Fx & portfolio adj.) to 12.328 billion euros / EBITDA before special items down 6.2 percent to 4.118 billion euros due to currency / Strong sales growth at Crop Science (Fx & portfolio adj.) in improved market environment / Sales at Pharmaceuticals (Fx & portfolio adj.) at prior-year level / Consumer Health ahead of competition with continuous good performance / Net income advances by 40.3 percent to 2.089 billion euros / Core earnings per share decline by 3.0 percent to 2.59 euros / Outlook for 2021 confirmed » more
-
Tuesday - May 11, 2021
Not intended for U.S. and UK Media
Bayer presents expanded research and new approaches to advance cancer care at 2021 ASCO Annual Meeting
Updated long-term efficacy and safety data of larotrectinib (Vitrakvi™) for patients with TRK fusion cancer from an integrated dataset, sub-analyses for TRK fusion cancer patients with primary central nervous system (CNS) tumors and lung cancer, respectively, as well as updated results from an intra-patient comparison to be featured / In prostate cancer, a key therapeutic area for Bayer, the safety of the Targeted Alpha Therapy radium-223 dichloride (Xofigo™) in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) will be highlighted with data from the ongoing PEACE-III study; additional early-stage results in different tumor types to be presented / Additional research to highlight tolerability of darolutamide (Nubeqa™) from extended follow-up in the Phase III ARAMIS trial in non-metastatic castration-resistant prostate cancer (nmCRPC) as well as data from the ODENZA trial exploring patient preferences between darolutamide and enzalutamide in men with mCRPC / Data across other disease states on Bayer’s growing oncology portfolio with copanlisib, regorafenib and sorafenib will also be presented » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Thursday, August 5, 2021
Half-Year Report 2020
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV